Fibroblast Reporter System
Fibroblast Reporter System - Related Videos
15:43
Experimental Generation of Carcinoma-Associated Fibroblasts (CAFs) from Human Mammary Fibroblasts
0 Views •
Cited by 25 •
2011
Carcinoma-associated fibroblasts (CAFs) rich in myofibroblasts present within the tumour stroma, play a major role in driving tumour progression. We developed a coimplantation tumour xengraft model for experimentally generating CAFs from human mammary fibroblasts. The protocol describes how to establish CAF myofibroblasts that acquire an ability to promote tumourigenesis.
09:38
Direct Reprogramming of Mouse Fibroblasts into Melanocytes
0 Views •
Cited by 2 •
2021
Here, we describe an optimized direct reprogramming system for melanocytes and a high-efficiency, concentrated virus packaging system that ensures smooth direct reprogramming.
05:54
Rapid Culturing of Primary Murine Melanocytes and Fibroblasts: Isolating Melanocytes and Fibroblasts from Whole Murine Skin Sample
0 Views •
2023
This video describes the rapid method to isolate and culture the melanocytes and fibroblast simultaneously from the postnatal mouse pup’s skin. These cells can be maintained and manipulated in vitro to study skin cell biology, wound healing, and melanoma.
06:04
Murine Dermal Fibroblast Isolation by FACS
0 Views •
Cited by 28 •
2016
Fibroblast behavior underlies a spectrum of clinical entities, but they remain poorly characterized, largely due to their inherent heterogeneity. Traditional fibroblast research relies upon in vitro manipulation, masking in vivo fibroblast behavior. We describe a FACS-based protocol for the isolation of mouse skin fibroblasts that does not require cell culture.
09:43
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
0 Views •
Cited by 1 •
2025
This protocol provides a comprehensive procedure to isolate, expand, and immortalize fibroblasts from radical prostatectomies. Moreover, it describes assays developed to assess the functional effects of fibroblast-tumor cell crosstalk, taking advantage of both treatment with conditioned medium and co-culturing.
FAQs
The regulatory DNA acts as a decision point that links fibroblast-associated gene expression or pathway activation to reporter output. When the relevant regulatory program becomes active, the linked fluorescent or luminescent signal changes, allowing investigators to monitor a biological process that would otherwise be difficult to observe directly in cultured cells or tissues.
Depending on the regulatory response being monitored, the signal can provide information about fibroblast identity, cellular activity, or changes in cell state. This makes the system useful for examining how fibroblasts respond during wound repair, tissue remodeling, fibrosis, or tumor-associated processes rather than treating all fibroblasts as biologically equivalent.
A measurable signal converts otherwise hidden molecular or cellular changes into an observable readout. Fluorescent or luminescent output can therefore support monitoring of pathway activation and comparison of fibroblast-related responses across cultured cells or tissues. This quantifiable format is especially valuable when researchers need to follow biological changes during disease studies or treatment evaluation.
The workflow centers on using fibroblast-related regulatory DNA connected to a reporter, applying the system in cultured cells or tissues, and monitoring the resulting signal. Investigators then interpret changes in fluorescence or luminescence as evidence of altered fibroblast-associated gene expression, pathway activation, or cell state under the conditions being studied.
Researchers can apply it when they need to examine fibroblast behavior in wound repair, tissue remodeling, fibrosis, or tumor microenvironments. The model helps connect fibroblast-associated molecular activity with disease-related tissue changes, making it relevant for investigating how fibroblasts influence disease progression and for exploring biological mechanisms that may affect treatment response.
In drug studies, changes in reporter output can help reveal whether a treatment alters fibroblast-associated activity or pathway activation. This supports screening candidate compounds and performing mechanism-based evaluations of anti-fibrotic therapies. The approach can also contribute to assessing treatment response by linking drug exposure with measurable changes in fibroblast-related biological processes.